Safety & Efficacy of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in LVAD Recipients
Phase of Trial: Phase II
Latest Information Update: 03 Apr 2017
At a glance
- Drugs Rexlemestrocel-L (Primary)
- Indications Heart failure
- Focus Adverse reactions; Therapeutic Use
- 03 Apr 2017 According to a Mesoblast media release, this trial is funded by in a United States National Institutes of Health (NIH).
- 27 Feb 2017 According to a Mesoblast media release, results of this trial will be used to guide the discussions with the United States Food and Drug Administration (FDA) in line with the 21st Century Cures Act for potential accelerated approval pathways for MPC-150-IM.
- 27 Feb 2017 According to a Mesoblast media release, an enrollment of this trial is expected to be completed during 1H 2017 with a data read-out planned in 2H 2017.